Human immunodeficiency virus type 1 (HIV-1) is a human retrovirus and the causative agent of the acquired immunodeficiency syndrome. Genetic analysis has revealed that the HIV-1 LTR contains a potential negative regulatory element (NRE) with an E box, the recognition sequence for the helix-loophelix (HLH) family of transcription factors. Furthermore, the upstream stimulatory factor (USF) has been implicated as a negative regulator of HIV-1 expression. Here, we report that the NRE is a composite element and that both C/EBPδ and USF can specifically bind to the NRE. The recognition sequence for C/EBPδ overlaps with the E box in the NRE of HIV-1. Competition experiments showed that either USF or C/EBPδ binds to this NRE but not both together.
Introduction
The human immunodeficiency virus type 1 (HIV-1) is a human retrovirus and the etiological agent of the acquired immunodeficiency syndrome (AIDS) [1] .
Several human cellular proteins regulate HIV-1 gene expression and viral replication by their interaction with the viral 5'-long terminal repeat (LTR) [2] [3] [4] . This LTR can be divided into three major regulatory regions, based on the overall effects of each region on HIV-1 gene expression [2] . These HIV-1 LTR regions are defined as the transactivation responsive region (TAR), the core region, and the modulatory region. Several defined elements involved in binding of cellular transcription factors have been found in the modulatory region [2] [3] [4] . One of them is the region located between nucleotide positions -167 and -423, which has a negative effect on the rate of transcription in vivo and in vitro [5] . This negative regulatory region contains a number of recognition sequences for cellular transcription factors [2, 4] . The best characterized of these, is the region of the HIV-1 LTR extending from nucleotide positions -159 to -173. Deletion of these sequences results in an increase of both reporter gene transcription and viral replication as compared to results of similar experiments with sequences of the wild-type strain [6] [7] [8] . We will further refer to this element within the negative regulatory region as the negative regulatory element (NRE); this element contains a CACGTG motif. This motif which contains the consensus sequence CANNTG (also referred to as an E box) is characteristic of the recognition sequence of transcription factors possessing helix-loop-helix (HLH) DNAbinding domains [9] . It has been shown that several proteins are able to bind to the NRE and it has been suggested that upstream stimulatory factor (USF) could be one of the proteins binding to the E box within the NRE [6] .
In this study, we show that the NRE is a composite element consisting of an overlapping E box and a C/EBP site. We show that C/EBPδ can transactivate the HIV-1 LTR in the presence of Tat in NCI-H82 cells. Both USF and C/EBPδ can bind to an oligonucleotide containing the overlapping E box -C/EBP site of the NRE. The binding of C/EBPδ and USF to their cognate sites within the composite element is mutually exclusive. Based on our in vitro data, we propose a mechanism according to which USF or C/EBPδ (and likely other members of the C/EBP family) binds to the NRE of HIV-1 LTR depending on their expression level and the cellular transcription factor context, thereby regulating the expression level of HIV genes.
Results

C/EBPδ transactivates the HIV 1 LTR in the presence of Tat
The experiments described in this study were inspired by the initial observation that the HIV-1 LTR in the presence of Tat was more active in HepG2 cells as compared to NCI-H82 cells (Fig. 1A) . A computer search revealed that the E box within the NRE was not a simple element but that it overlapped with a putative (C/EBP) binding element, suggesting that the NRE was a composite USF-C/EBP element. Co-transfection experiments were performed in order to investigate whether C/EBP family members were able to transactivate the HIV-1 LTR. NCI-H82 cells were transfected with pSupexp-LUC, which contained both the luciferase gene as a reporter under control of the HIV-1 LTR and the tat gene under control of the SV40 early promoter in one vector, together with an expression vector for C/EBPα, C/EBPβ, C/EBPδ, or SP1.
Figure 2
Analysis of binding of C/EBPδ to the HIV-1 NRE using electromobility shift assay (EMSA Co-transfection with the SP1 expression vector had no effect, most likely due to the high endogenous levels of SP1 protein in these cells. The transactivation effect of C/EBPδ was not observed in HepG2 cells (not shown). An explanation for this discrepancy between the two cell lines might be that there are already sufficient amounts of other C/EBP family members in the HepG2 cells (see below). 
C/EBPδ can bind to the HIV-1 NRE
In order to show that the transactivation of the LTR by C/EBPδ could be due to a direct effect, we determined whether C/EBPδ was able to bind to an oligonucleotide containing a putative C/EBP binding site in the NRE. C/EBPδ was expressed by in vitro transcription and translation and subjected to EMSA. The production of C/EBPδ from the T7 expression plasmid was verified by translation in the presence of [ 35 S]methionine and SDS-PAGE ( Fig. 2A) . As expected, a protein of about 32 kDa was synthesized in the reticulocyte lysate. As a positive control for C/EBPδ binding, we sought a wellcharacterized C/EBP binding element that would efficiently interact with C/EBP proteins (OL-C/EBP) [16, 17] . C/EBPδ was capable to indeed bind to both OL-C/EBP, containing a high affinity C/EBP binding site and OL-HIV NRE, containing the overlapping E box and the putative C/EBP-binding site (Fig.2B lanes 1  and 3). (B) Transactivation of the HIV-1 LTR by C/EBPδ. Effector plasmids pMSV-C/EBPα, pMSV-C/EBPβ, pMSV-C/EBPδ, and pCMV-SP1 were cotransfected with pSupexp-LUC in NCI-H82 cells. Forty eight hours after transfection, cells were assayed for luciferase activity. Promoter activities are expressed relative to that of pCMV-SP1 (100%). Each bar represents the mean and standard deviation of four separate transfection experiments in which three or six separate wells were used per effector plasmid.
As can be seen in Figure 1B , C/EBPδ was found to transactivate the HIV-1 LTR about 5-fold in NCI-H82 cells. The effect was specific, since it was not observed for C/EBPβ. C/EBPα, on the other hand, could transactivate the HIV-1 LTR about 3-fold. However, the effect of C/EBPα varied between experiments. Binding C/EBPδ and USF to the HIV-1 NRE. Nuclear extracts of rat liver or NCI-H82 cells were incubated in EMSA buffer for 15 min on ice with or without competitor oligonucleotides. After addition of radiolabeled OL-C/EBP or OL-HIV NRE and incubation on ice for 15 min, DNA-protein complexes were analyzed by EMSA.
In order to determine whether the protein(s) binding to OL-HIV NRE were binding to the putative C/EBP site, competition experiments were performed with OL-C/EBP. We observed that unlabeled OL-C/EBP was not able to compete for the binding of the liver or NCI-H82 proteins to radiolabeled OL-HIV NRE ( The binding of C/EBPδ to both oligonucleotides was specific, as it was competed by excess unlabeled oligonucleotide (not shown).
16), showing that the major shifted complex produced when liver extract was incubated with OL-HIV NRE was not formed because of binding to the consensus C/EBP binding site in this oligonucleotide. However, we consistently (after long exposure times) observed that when binding reactions were performed with liver nuclear extracts and OL-HIV NRE, besides the major shifted band, there was also a smear visible that resembled the typical shifted smear observed when liver C/EBP proteins bind to OL-C/EBP. Interestingly, as can be seen in Fig. 3 (compare lanes 7, 9 and 10), when the binding of liver proteins to radiolabeled OL-HIV NRE was competed with unlabeled OL-C/EBP, but not with OL-AP4, the typical smear disappeared leaving the major shifted complex intact. Therefore, these data suggest that C/EBP family members were forming complexes with OL-HIV NRE but that also another nonrelated protein was binding to this oligonucleotide.
When binding reactions were performed with nuclear extracts of rat liver and OL-C/EBP, a broad smear appeared consisting of multiple shifted bands (Fig. 2B , lane 7 and Fig. 3, lane 15 ), in agreement with the reported high levels of C/EBP proteins in liver cells. On the other hand, when binding reactions were performed with nuclear extract of NCI-H82 cells and OL-C/EBP, no shifted bands appeared, suggesting that there are very low levels of C/EBP proteins in these cells. The low levels of C/EBP proteins in NCI-H82 may explain why C/EBPδ is able to transactivate the HIV-1 LTR in these cells but not in HepG2 cells.
The binding of liver nuclear extracts with OL-HIV NRE, resulted unexpectedly in the formation of one major complex (Fig. 2B, lane 5) . The mobility of this shifted complex was lower than that obtained with C/EBPδ, indicating that some other protein (with a higher molecular weight than C/EBPδ) was interacting with the oligonucleotide. The interaction of this protein with OL-HIV NRE was specific, as it was competed by an excess of the unlabeled oligonucleotide (Fig. 3,  lanes 1 and 2) . The incubation of NCI-H82 nuclear Both proteins were not binding simultaneously to the oligonucleotide, as we could not detect ternary complexes of lower mobility to account for this possibility.
Figure 4
Identification of USF as the factor binding to the HIV-1 NRE. Nuclear extracts of rat liver, NCI-H82 cells or HepG2 cells, or recombinant USF1 (10ng) were incubated in EMSA buffer for 15 min on ice in the presence or absence of an antiserum to USF1 or non-immune rabbit serum. After addition of radiolabeled OL-HIV NRE and incubation on ice for 15 min, DNA-protein complexes were analyzed by EMSA. r-USF, recombinant USF1-310; α-USF, antiserum to USF1, n.s., non-immune rabbit serum.
We conclude, therefore, that C/EBPδ (and other C/EBP family members) can bind to the HIV NRE but that in nuclear extracts predominantly another protein binds to this element.
USF and C/EBPδ compete for the NRE
It has been suggested previously that USF may be the factor binding to the E box within the NRE in the HIV-1 LTR [6] . USF is a member of the HLH family of transcription factors [18] . The family of HLH proteins has been classified into two subclasses according to their cognate DNA binding site. For example, AP4 and MyoD both bind to the palindromic core sequence CAGCTG (class A), whereas c-Myc and USF bind to the core sequence CACGTG (class B) [19 and references therein].
In order to determine to which class of the HLH family the factor binding to the HIV NRE oligonucleotide belonged, we compared the ability of oligonucleotides containing a CACGTG or a CAGCTG motif to compete for the binding. The USF-binding element from the adenovirus major late promoter (class B) and a putative AP4-binding element (class A) from the NSP gene (also called RTN1), were used as competitors (OL-USF and OL-AP4, respectively). The major shifted complex from liver nuclear extract (but not the smear) and the doublet from NCI-H82 disappeared completely when OL-USF was used as a competitor (Fig. 3, lanes  1 and 3, and lanes 4 and 6) . In contrast, OL-AP4 was not able to compete efficiently for the binding (Fig. 3,  lanes 7 and 9 and lanes 11 and 13) , suggesting that the protein binding to OL-HIV NRE belonged to the class B of HLH proteins. Although the unlabeled OL-USF oligonucleotide could abolish the major shifted complex, the typical C/EBP smear remained intact (Fig.3, lanes 1 and 3) . This is the converse observation as described above, where the typical C/EBP smear but not the major shifted band could be abolished by addition of unlabeled OL-C/EBP oligonucleotide to the binding reaction containing liver nuclear extract and radiolabeled OL-HIV NRE. In order to verify that the major shifted complex contained USF, a specific antiserum raised against USF1 was added to the binding reactions. As a negative control, we used normal rabbit serum. The addition of antiserum raised against USF1 to the binding reactions containing extracts of liver or NCI-H82 cells completely abolished the formation of the shifted singlet or doublet, respectively, suggesting that all these complexes contain USF1. Purified USF from HeLa cells has been reported to contain two proteins of 43 and 44 kD [20, 21] , each of which binds DNA specifically and with identical DNA-binding properties [20, 21] . The smaller 43-kDa protein has been cloned and sequenced and is referred to as USF1 [18] . The larger protein (44 kDa) has also been cloned and sequenced and is referred to as USF2 [22, 23] . The two proteins are very similar in their dimerization and DNA-binding domains but are quite divergent in their Nterminal amino acid sequences. Examination of their tissue and cell-type distribution revealed that expression of both USF species is ubiquitous. Moreover, the two USF forms homodimerize and heterodimerize with each other and different ratios of USF homo-and heterodimers are found in different cells [23] . In this context, it is interesting to note that we observed a singlet while performing EMSAs with rat liver nuclear extracts or recombinant USF1, but doublets when using NCI-H82 cells and also HepG2 cells (Fig. 4, lanes 12 and  13) . On the basis of the migration pattern of the shifted complexes with nuclear extracts and recombinant USF1, and taking into account the reported mobility of the USF homo-and heterodimers, we conclude that the relative expression levels of the two USF forms differ between rat liver and NCI-H82 cells but also surprisingly with HepG2 cells. Sirito et al. [22] concluded that Hela cells contain prominently USF1 (43 kDa) and that therefore, in EMSAs, no UFS2 homodimers are observed. The shifted doublet of NCI-H82 and HepG2 cells is very similar to that reported for HeLa cells, so we suggest that in NCI-H82 and HepG2 cells, USF1 is likely to be the prominent form. For rat liver, however, we observed a singlet that migrated identically to the USF1-USF2 heterodimer, suggesting that a more equimolar level of both USF forms is present in hepatocytes.
When liver extracts were incubated with the anti-USF antiserum, the shifted complex disappeared but the smear of bands identical to the one observed after binding of C/EBP family members to the C/EBP oli-gonucleotide remained intact (Fig. 4, lanes 7 and 8) . The effect of adding anti-USFantiserum to the binding reactions was the same as adding unlabeled OL-USF, in that the major shifted complex disappeared but a smear typical of C/EBP proteins remained intact (compare Fig. 3 lanes 1 and 3 with Fig. 4 lanes 7 and 8) . These data suggest that the remaining smear is the result of C/EBP proteins binding to the NRE, which appeared to be increased somewhat after USF has been bound and inactivated by the antibodies. In virto translated C/EBPδ was added to nuclear extracts of rat liver, or to recombinant USF and incubated in EMSA buffer for 15 min on ice in the presence or absence of antiserum to USF1 ornon-immune rabbit serum. Afer addition of radiolabeled OL-HIV NRE and incubation on ice for 15 min, DNA-protein complexes were analyzed by EMSA. r-USF, recombinant USF1-310; α-USF, antiserum to USF1, n.s., non-immune rabbit serum. TnT, coupled transcription and translation reticulocyte extract.
One way to explain the binding of C/EBP proteins to radiolabeled OL-HIV NRE after selective disruption of USF binding is that USF and C/EBP proteins may compete for binding at the same site. This is likely in light of the fact that the USF recognition sequence and the C/EBP recognition sequence are partially overlapping. Therefore, we determined whether C/EBPδ can displace USF from the NRE. We expressed C/EBPδ by in vitro transcription and translation and added this protein to binding reactions. Addition of C/EBPδ to binding reactions containing nuclear extracts of liver or NCI-H82 cells and radiolabeled OL-HIV NRE resulted in an almost complete disappearance of the USF-NRE complex. Instead, a faster migrating complex appeared and it had an identical mobility as the one obtained when C/EBPδ alone was incubated with radiolabeled OL-HIV NRE (Fig. 5 lanes 1 and 2, and lanes 9 and  11) . No slower migrating complexes were observed, suggesting that either USF or C/EBPδ was bound to the oligonucleotide but not both. The addition of C/EBPδ together with anti-USF antiserum (but not normal rabbit serum) to the binding reactions resulted in the complete disappearance of the shifted complex that was formed by USF binding to radiolabeled OL-HIV NRE (Fig. 5 lanes 3 and 4) . Furthermore, binding of C/EBPδ to radiolabeled OL-HIV NRE was not altered by addition of anti-USF1 antiserum to the binding reaction. This strongly suggests, but does not prove unambiguously, that the fast migrating complex did not consist of a heterodimer between USF and C/EBPδ. When large amounts of recombinant USF was added to binding reactions containing C/EBPδ and USF antiserum, only a limited amount of shifted complex was observed and a slower migrating complex appeared (Fig. 5 lanes  13-15) . This could mean that the proteins can physically interact with each other at high concentrations. Although the antibody-USF complexes may simply be trapping the C/EBPδ in our in vitro assays, the level of USF used does not seem to be nonphysiological. The concentration of the recombinant USF added in our EMSAs was in the nanomolar range while in the HeLa nucleus the USF concentration has been estimated as 0.5 µM [21, 24] . Therefore, we cannot exclude the possibility yet that under particular conditions, USF may directly interact with C/EBPδ at the protein level. Detailed studies will be necessary in order to resolve this issue.
Discussion
We have presented here three lines of evidence suggesting that C/EBP family members can be involved in the functioning of the LTR of HIV-1. Firstly, C/EBPδ is able to transactivate the HIV-1 LTR in the presence of Tat in NCI-H82 cells. NCI-H82 cells contain low levels of endogenous C/EBP proteins, in accordance, the LTR is not very active and can therefore readily be transactivated by C/EBPδ. On the other hand, the HIV-1 is more active in HepG2 cells, in accordance, hepatoma cells contain higher levels of C/EBP proteins and in these cells co-transfection with a C/EBPδ expression vector does not result on transactivation. At this point, it should also be noted that it has been shown by DNase footprinting analysis that there are two additional C/EBP binding sites in the HIV-1 LTR [25] . In this context, we would like to emphasize that mutagenesis of the HIV-1 LTR has to be performed in order to demonstrate conclusively that the observed transcriptional activation of C/EBPδ was due to prevention of USF binding to the NRE. Mutational analysis of the HIV-1 LTR has shown that at least one of the three C/EBP sites is required for normal LTR transcription and that the two 3' C/EBP sites (including the one within the NRE ) are functionally equivalent [26] . Secondly, we have shown that C/EBPδ can bind specifically to the HIV-1 NRE. Thirdly, we have shown that USF can bind to the canonical E box within the NRE, and that C/EBPδ can compete for this binding by binding to a C/EBP recognition sequence that overlaps with the E box.
In view of the high levels of C/EBP proteins in liver, it was rather surprising that binding of the NRE, which contained a consensus C/EBP binding site resulted mainly in a single specific complex produced by USF binding. This is even more so, since it is likely that liver expresses also other E-box binding proteins. This indicates that promoter context is very important for the binding of transcription factors to their recognition sequences. The overlapping nature of the USF binding site and the C/EBP binding site and our observation that in vitro C/EBPδ can displace USF from the NRE suggests that competition for binding to this complex element by different transcription factor family members may be of physiological relevance.
Materials and methods
Plasmids
To create pGL2-CMV-LUC, the Bglll-Hindlll fragment of pRC-CMV (Invitrogen) containing the human c tomegalovirus early promoter and enhancer was inserted into the multiple cloning site of pGL2-Basic (Promega), a promoter-and enhancer-less vector containing the firefly luciferase encoding sequence. To create pSupexp-LUC, the Nhel-BamHI (blunted) of pGL2-Basic, containing the luciferase coding region, was inserted into the multiple cloning site (Spel-Hpal) of pSupexp [10] (kindly provided by Dr. T Subramanian). The C/EBP expression vectors pMSV-C/EBPα, pMSV-C/EBPβ and pMSV-C/EBPδ [11] were kindly provided by Drs. S. L. McKnight and W.-C. Yeh. The SP1 expression vector pCMV-SP1, was kindly provided by R. Tjian and K. Goodrich.
y-
Cell lines, DNA transfer and transient gene expression. The HepG2 (human hepatocellular carcinoma) and NCI-H82 (human small cell lung carcinoma) cell lines were obtained from the American Type Culture Collection (ATCC) and grown according to the ATCC recommendations. Promoter activity of DNA fragments was assayed using transient gene expression, as described previously [12] .
Electromobility shift assay (EMSA)
The adenovirus major late promoter USF binding site (OL-USF) was created by annealing the oligonucleotides: 5'-TCGACGGTGTAGGCCACGTGACCGGGTGTAA-3' and its complementary strand (binding site for USF is in boldface type). The C/EBP binding site (OL-C/EBP) was created by annealing the oligonucleotides: 5'-GCTGCAGATTGCGCAATCTGCAGCA-3' and its complementary strand (binding site for C/EBPδ is in boldface type). The HIV-1 NRE containing the binding site for USF and C/EBPδ (OL-HIV NRE) was created by annealing the oligonucleotides: 5'-CCGCCTAGCATTTCATCACGTGGCCCG-3' and its complementary strand (binding site for USf is in boldface type, binding site for C/EBPδ is underlined). The neuroendocrine-specific gene (NSP) AP4 binding site (OP-AP4) was created by annealing the oligonucleotides: 5'-GAACCCACGGCCGGTGGGCCAGCTGGCCGACAG GCCCGAG-3' ant its complementary strand (binding site for AP4 in boldface type).
Electromobility shift assay was performed as described previously [12] . Nuclear extract of rat liver were prepared according to [13] and nuclear extract of cell lines were prepared according to [14] . Recombinant USF1 (full length 43-kDa form) and a specific anti-USF1 antiserum against the 43-kDa form) [14] were kindly provided by DRs. R. G. Roeder end P. Pognonec. When USF antiserum was used, 0.1µl was added (or 0.1µl normal rabbit serum as a control) to the binding reaction at the beginning together with the nuclear extract.
In vitro transcription and translation
In order to make C/EBPδ protein by in vitro transcription and translation, the EcoRI-BamHI fragment of pMSV-C/EBPδ containing the complete coding region of C/EBPδ was inserted into pGEM-3Zf(+) under the control of the bacteriophage T7 RNA polymerase promoter, creating pTnT-C/EBPδ. Plasmid DNA was added directly to transcription and translation coupled (TnT) reticulocyte lysate (Promega) and incubated for 90 min at 30°C. The correct synthesis of C/EBPδ was checked by carrying out translation in the presence of [ 35 S]methionine. In vitro translated products were analyzed by electrophoresis on 12% SDS-poyacrylamide gels. As a control, the reticulolcyte lysate was programmed to produce luciferase by using the pGL2-CMV-LUC plasmid and T7 RNA polymerase.
